An observational study in Acute Promyelocytic Leukemia and Chronic Myeloid Leukemia, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This cross-sectional study aims to establish and evaluate a standardized fluorescence in situ hybridization workflow for detection of PML::RARA in acute promyelocytic leukemia and BCR::ABL1 in chronic myeloid leukemia.
Acute promyelocytic leukemia is defined by the PML::RARA fusion, and chronic myeloid leukemia is defined by the BCR::ABL1 fusion. Fluorescence in situ hybridization (FISH) can detect these fusions rapidly on interphase cells.
This observational study will apply a standardized FISH workflow using dual-color dual-fusion probes for PML::RARA and BCR::ABL1. Laboratory-specific normal cut-off values will be established from control specimens, and the probes will be tested on confirmed positive specimens from newly diagnosed untreated patients.
135 studies on the registry are indexed under Leukemia, Promyelocytic, Acute; 17 are open to participants now.
This study's planned enrollment of 40 is below the median of 109 across 18 observational studies indexed under Leukemia, Promyelocytic, Acute.
Browse Leukemia, Promyelocytic, Acute studies →Assiut University is the lead sponsor of 5,092 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Newly diagnosed untreated patients with acute promyelocytic leukemia or chronic myeloid leukemia, and individuals without hematologic malignancy who have a normal karyotype, at Assiut University Hospitals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Newly diagnosed untreated patients with acute promyelocytic leukemia or chronic myeloid leukemia.
Individuals without hematologic malignancy who have a normal karyotype.
Number of nuclei showing positive FISH signal pattern
Number of interphase nuclei showing the expected positive signal pattern for PML::RARA or BCR::ABL1 by fluorescence in situ hybridization (out of 200 nuclei scored per case).
Time frame: Baseline
Normal cut-off values for FISH signals
Laboratory-specific normal cut-off values (percentage) for each fluorescence in situ hybridization signal pattern calculated from control specimens using the inverse beta function.
Time frame: Baseline
Number of cases with typical signal pattern
Number of confirmed positive cases showing the typical dual-fusion signal pattern by fluorescence in situ hybridization.
Time frame: Baseline
Inter-observer concordance rate
Percentage of agreement between two independent scorers for fluorescence in situ hybridization signal patterns.
Time frame: Baseline
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2027, 11 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leukemia, Promyelocytic, Acute →